Arcutis Biotherapeutics Inc (ARQT)

09:44 AM

Responsive Playbooks and the ARQT Inflection - news.stocktradersdaily.com

09:44 AM

07:36 AM

Why Arcutis Biotherapeutics Inc. stock appeals to dividend seekersJuly 2025 Trade Ideas & Daily Stock Momentum Reports - newser.com

07:36 AM

05:25 AM

Why Arcutis Biotherapeutics Inc. stock is trending among retail tradersFed Meeting & Weekly High Potential Stock Alerts - newser.com

05:25 AM

03:47 AM

Why Shares in Arcutis Biotherapeutics Surged Again This Week - Nasdaq

03:47 AM

Nov 20, 2025

Is Arcutis Biotherapeutics Inc. stock a buy for dividend growthBuy Signal & Comprehensive Market Scan Insights - newser.com

Nov 20, 2025

Nov 20, 2025

Dir Gilbert Files To Sell 16,532 Of Arcutis Biotherapeutics Inc [ARQT] - TradingView

Nov 20, 2025

Nov 20, 2025

Arcutis Biotherapeutics, Inc. (ARQT) Soars to 52-Week High, Time to Cash Out? - Yahoo Finance

Nov 20, 2025

Nov 20, 2025

Arcutis Zoryve cream sNDA accepted by FDA for pediatric plaque psoriasis - MSN

Nov 20, 2025

Nov 20, 2025

What moving averages say about Arcutis Biotherapeutics Inc.July 2025 Reactions & Technical Entry and Exit Alerts - newser.com

Nov 20, 2025

Nov 19, 2025

Arcutis Biotherapeutics (ARQT) Price Target Increased by 32.62% to 31.62 - MSN

Nov 19, 2025

Nov 19, 2025

10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga

Nov 19, 2025

Nov 19, 2025

Vitiligo Market Analysis and Forecasts 2025-2035 Featuring Abbvie, Incyte, Amgen, Pfizer, Clinuvel Pharmaceuticals, TWi Biotech, and Arcutis BiotherapeuticsResearchAndMarkets.com - The AI Journal

Nov 19, 2025

Nov 19, 2025

Will earnings trigger a reversal in Arcutis Biotherapeutics Inc.Portfolio Value Summary & AI Based Buy/Sell Signal Reports - newser.com

Nov 19, 2025

Nov 19, 2025

Historical volatility pattern of Arcutis Biotherapeutics Inc. visualized2025 Breakouts & Breakdowns & Risk Controlled Stock Alerts - newser.com

Nov 19, 2025

Nov 18, 2025

Arcutis Biotherapeutics Inc Stock Analysis and ForecastMarket Sentiment Indicators & Double Or Triple Returns - earlytimes.in

Nov 18, 2025

Nov 18, 2025

Arcutis Biotherapeutics stock hits 52-week high at $27.09 By Investing.com - Investing.com India

Nov 18, 2025

Nov 18, 2025

Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average - sharewise.com

Nov 18, 2025

Nov 18, 2025

Krishnamohan Neha sells Arcutis Biotherapeutics (ARQT) stock for $939k By Investing.com - Investing.com South Africa

Nov 18, 2025

Nov 17, 2025

[Form 4] Arcutis Biotherapeutics, Inc. Insider Trading Activity - Stock Titan

Nov 17, 2025

Nov 17, 2025

Krishnamohan Neha sells Arcutis Biotherapeutics (ARQT) stock for $939k - Investing.com

Nov 17, 2025

Nov 17, 2025

Dir Krishnamohan Sells 40,504 ($939.5K) Of Arcutis Biotherapeutics Inc [ARQT] - TradingView

Nov 17, 2025

Nov 17, 2025

Arcutis Biotherapeutics stock rises on FDA acceptance of pediatric psoriasis drug - Investing.com

Nov 17, 2025

Nov 17, 2025

Arcutis Biotherapeutics Says FDA Accepts Supplemental New Drug Application for Zoryve - MarketScreener

Nov 17, 2025

Nov 17, 2025

FDA Accepts sNDA for Roflumilast Cream 0.3% in Children Ages 2 to 5 with Psoriasis - HCPLive

Nov 17, 2025

Nov 17, 2025

FDA Evaluates Arcutis (ARQT) Application to Expand ZORYVE Use in Young Children - GuruFocus

Nov 17, 2025

Nov 17, 2025

FDA accepts Arcutis’ application for psoriasis cream in children By Investing.com - Investing.com Canada

Nov 17, 2025

Nov 17, 2025

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 - The Manila Times

Nov 17, 2025

Nov 17, 2025

Arcutis Biotherapeutics Announces PDUFA Target Action Date for ZORYVE® Cream 0.3% Indication Expansion in Pediatric Plaque Psoriasis - Quiver Quantitative

Nov 17, 2025

Nov 17, 2025

Arcutis (NASDAQ: ARQT) sNDA for ZORYVE Cream Accepted, PDUFA June 29 2026 target date - Stock Titan

Nov 17, 2025

Nov 16, 2025

What’s the recovery path for long term holders of Arcutis Biotherapeutics Inc.Portfolio Return Report & High Accuracy Swing Entry Alerts - newser.com

Nov 16, 2025

Nov 16, 2025

Is Arcutis Biotherapeutics Inc. stock undervalued vs historical averages2025 Short Interest & Risk Adjusted Buy and Sell Alerts - newser.com

Nov 16, 2025

Nov 16, 2025

What the charts say about Arcutis Biotherapeutics Inc. todayEntry Point & AI Forecasted Entry/Exit Points - newser.com

Nov 16, 2025

Nov 15, 2025

How Arcutis Biotherapeutics Inc. stock reacts to global recession fears2025 Buyback Activity & Weekly Return Optimization Alerts - newser.com

Nov 15, 2025

Nov 15, 2025

How Arcutis Biotherapeutics Inc. stock reacts to Fed rate cuts2025 Geopolitical Influence & Fast Entry Momentum Alerts - newser.com

Nov 15, 2025

Nov 14, 2025

Has Arcutis Biotherapeutics Inc. found a price floorJuly 2025 Setups & Safe Swing Trade Setup Alerts - newser.com

Nov 14, 2025

Nov 14, 2025

Multi asset correlation models including Arcutis Biotherapeutics Inc.July 2025 Closing Moves & Stepwise Trade Execution Plans - newser.com

Nov 14, 2025

Nov 14, 2025

Why Arcutis Biotherapeutics Inc. stock attracts high net worth investorsPortfolio Value Report & Risk Adjusted Buy and Sell Alerts - Fundação Cultural do Pará

Nov 14, 2025

Nov 14, 2025

Is Arcutis Biotherapeutics Inc. a candidate for recovery playWall Street Watch & Low Drawdown Trading Strategies - newser.com

Nov 14, 2025

Nov 13, 2025

Arcutis completes enrollment in infant atopic dermatitis study By Investing.com - Investing.com Nigeria

Nov 13, 2025

Nov 13, 2025

Executive VP & Chief Commercial Officer Of Arcutis Biotherapeutics Sold 40% Of Their Shares - simplywall.st

Nov 13, 2025

Nov 13, 2025

Peering Into Arcutis Biotherapeutics Inc's Recent Short Interest - Benzinga

Nov 13, 2025